Introduction
============

Genes for AmpC β-lactamases are commonly found on the chromosomes of several family members of Enterobacteriaceae such as *Enterobacter* spp. and non-fermenting bacteria such as *Pseudomonas aeruginosa*,[@dky317-B1] and AmpC overproduction provides these pathogens with resistance to penicillin, cephalosporins and monobactams as well as carbapenems especially in the presence of porin loss.[@dky317-B2]^,^[@dky317-B3] These AmpC-producing isolates are problematic because they are reported to become resistant during antibiotic therapy owing to AmpC overproduction.[@dky317-B4]

Cefiderocol (CFDC, S-649266), a novel catechol-substituted siderophore cephalosporin, possesses *in vitro* activity against a wide variety of Gram-negative bacteria including carbapenem-resistant Enterobacteriaceae and MDR non-fermenting bacteria that produce various β-lactamases such as KPC or NDM carbapenemases, ESBLs and AmpC β-lactamases.[@dky317-B5]

Cefiderocol possesses potent activity with MIC~90~s of ≤1 mg/L for clinical isolates of *P. aeruginosa* and *Enterobacter cloacae* collected in North America and Europe between 2014 and 2015, and also shows a comparable MIC~90~ for meropenem-non-susceptible isolates.[@dky317-B5]^,^[@dky317-B6] We have revealed that cefiderocol activity against carbapenemase-resistant bacteria is owing to its relatively high stability against carbapenemases as well as its efficient penetration through the outer membrane via active iron-transport systems, but the degree to which cefiderocol is hydrolysed by AmpC β-lactamases has not been investigated.[@dky317-B7] Here, we reveal cefiderocol features relating to antibacterial activity against AmpC overproducers, stability against AmpC β-lactamases, and propensity for AmpC induction for *E. cloacae* and *P. aeruginosa*.

Materials and methods
=====================

Bacterial strains and antibiotics
---------------------------------

*P. aeruginosa* SR24883 and SR24 were clinical isolates from Japan; *E. cloacae* 1480700 was kindly provided by GlaxoSmithKline plc (USA). *P. aeruginosa* ATCC 27853 and *E. cloacae* ATCC 13047 were obtained from the ATCC. *P. aeruginosa* SR24-12 was obtained by selecting the cefotaxime-resistant mutant from SR24. *E. cloacae* 1480700-4 was obtained by selecting the ceftazidime-resistant mutant from 1480700. The increases in β-lactamase activity of these mutants were detected by nitrocefin degradation. Transposon-insertion mutant strains of *P. aeruginosa* PAO1 were provided by the University of Washington.[@dky317-B10] The *ampC*-deficient mutant strain AC2064 was constructed from *P. aeruginosa* PAO1 by homologous recombination.[@dky317-B11] Cefiderocol was synthesized at Shionogi & Co., Ltd (Osaka, Japan). Commercial-grade antibiotics aztreonam, cefepime, cefotaxime, ceftazidime, cefalotin, imipenem and meropenem were obtained from commercial sources.

MICs
----

MICs were determined by broth microdilution according to CLSI guidelines.[@dky317-B12]^,^[@dky317-B13] For the determination of cefiderocol MIC, iron-depleted CAMHB (ID-CAMHB) was prepared as previously described and used according to the CLSI's recommendation.[@dky317-B9] The quality-control MIC ranges of cefiderocol using ID-CAMHB approved by the CLSI were 0.06--0.5 mg/L for both *Escherichia coli* ATCC 25922 and *P. aeruginosa* ATCC 27853.[@dky317-B14]

Kinetic parameters of AmpC β-lactamase
--------------------------------------

Hydrolysis of β-lactam antibiotics was detected by monitoring the changes in the absorbance of β-lactam solution by spectrophotometry (U-3010, Hitachi, Japan). The wavelengths and molar extinction coefficients (Δε) have been reported previously.[@dky317-B8] The steady-state kinetic parameters (*k*~cat~ and *K*~m~) were determined using the Hanes--Woolf plot of the Michaelis--Menten equation.[@dky317-B15] For poorly hydrolysing substrates, the competitive inhibition constant (*K*~i~) instead of *K*~m~ was determined in the presence of 100 μM cefalotin as a reporter substrate. *k*~cat~ was determined at \>5-fold higher concentration than used for the *K*~i~ value. The AmpC β-lactamases purified from *E. cloacae* P99 and *P. aeruginosa* SR24-12 were used.

AmpC induction
--------------

The propensity for AmpC induction was evaluated by double disc diffusion assay and nitrocefin degradation assay (for details of the procedure, see the Supplementary data available at *JAC* Online). 3-Aminophenylboronic acid (APB; Tokyo Chemical Industry, Japan) was used for the inhibition of AmpC β-lactamase.[@dky317-B1]

Results and discussion
======================

In *P. aeruginosa*, overproduction of chromosomal AmpC is known to be the cephalosporin resistance mechanism that occurs during exposure to β-lactam antibiotics which is caused by the inactivation of genes that regulate the expression of AmpC, such as *ampD* and *dacB*.[@dky317-B16] To evaluate the effect of overproduction of chromosomal AmpC on the *in vitro* activity of cefiderocol, MICs for isogenic mutant strains of *P. aeruginosa* were determined \[Table [1](#dky317-T1){ref-type="table"} and Table [S1](#sup1){ref-type="supplementary-material"} (available as [Supplementary data](#sup1){ref-type="supplementary-material"} at *JAC* Online)\]. MICs of ceftazidime and cefepime for PAO1 were increased 4- to 16-fold by inactivation of *ampD* (PW8615) and *dacB* (PW6111), whereas cefiderocol MICs were little affected by these inactivations (≤2-fold increase for either *ampD* or *dacB*). The effect of the *ampC* gene inactivation on the MICs of cefiderocol as well as ceftazidime and cefepime was limited (≤2-fold decrease), which was different from imipenem, which showed an 8-fold MIC decrease. These results suggest that the activity of ceftazidime, cefepime and imipenem is reduced by the induced levels of AmpC, whereas the activity of cefiderocol is not. Similar results were demonstrated against the AmpC-overproducing mutants isolated from clinical isolates of *P. aeruginosa* and *E. cloacae* (Table [1](#dky317-T1){ref-type="table"}). The difference between MICs of cefiderocol for parental strains and those for their derivative isolates were ≤4-fold (*P. aeruginosa* SR24 and *E. cloacae* 1480700). On the other hand, MICs of ceftazidime, cefepime and aztreonam for AmpC-producing isolates were 16-fold higher or more than those for parental strains. Table 1.MICs for clinical strains and isogenic mutant strainsSpeciesStrainCharacteristicMIC (mg/L)cefiderocolceftazidimecefepimeimipenemmeropenemaztreonam*P. aeruginosa*PAO10.1251110.54*P. aeruginosa*PW8615*ΔampD* (Tn)0.25164118*P. aeruginosa*PW6111*ΔdacB* (Tn)0.2516810.516*P. aeruginosa*PW7953*ΔampC* (Tn)0.063120.1250.52*P. aeruginosa*SR240.1251110.0634*P. aeruginosa*SR24-12AmpC high producer0.125\>32160.50.125\>32*E. cloacae*14807000.250.50.0630.50.0630.125*E. cloacae*1480700-4AmpC high producer13210.50.06332[^1][^2]

To understand the differences in antibacterial activity against AmpC-overproducing strains between cefiderocol and ceftazidime, the kinetic parameters of AmpC β-lactamases derived from *P. aeruginosa* SR24-12 and *E. cloacae* P99 were examined (Table [2](#dky317-T2){ref-type="table"}). In the case of *P. aeruginosa* AmpC, although hydrolysis of cefiderocol, ceftazidime and cefepime was not detected, the affinities (*K*~i~) of cefiderocol were 40- and 17-fold lower than those of ceftazidime and cefepime, respectively. In the case of *E. cloacae* AmpC, the affinities of cefiderocol were \>940- and \>8-fold lower than those of ceftazidime and cefepime, respectively, and the hydrolysis of cefiderocol was not detected whereas that of ceftazidime and cefepime was detected. These results indicate that the relatively lower affinity of cefiderocol for the AmpC β-lactamase of *P. aeruginosa* and *E. cloacae* may contribute to the excellent antibacterial activity of cefiderocol against AmpC-overproducing strains. Table 2.Kinetic parameters of AmpC β-lactamaseβ-LactamaseAntibacterial agent*k*~cat~ (s^−1^)[^a^](#tblfn4){ref-type="table-fn"}*K*~m~ or *K*~i~ (μM)[^a^](#tblfn4){ref-type="table-fn"}*k*~cat~/*K*~m~ or *K*~i~ (μM^−1^ s^−1^)AmpC (*P. aeruginosa*)cefiderocolNH[^b^](#tblfn5){ref-type="table-fn"}214 ± 49.6[^c^](#tblfn6){ref-type="table-fn"}NDceftazidimeNH[^b^](#tblfn5){ref-type="table-fn"}5.3 ± 1.0[^c^](#tblfn6){ref-type="table-fn"}NDcefepimeNH[^b^](#tblfn5){ref-type="table-fn"}12.2 ± 0.1[^c^](#tblfn6){ref-type="table-fn"}NDcefalotin95.4 ± 9.324.5 ± 3.23.89meropenemNH[^b^](#tblfn5){ref-type="table-fn"}1.7 ± 0.4[^c^](#tblfn6){ref-type="table-fn"}NDP99 (*E. cloacae*)cefiderocolNH[^b^](#tblfn5){ref-type="table-fn"}\>1700[^d^](#tblfn7){ref-type="table-fn"}NDceftazidime(2.7 ± 0.49) × 10^−3^1.8 ± 0.099[^c^](#tblfn6){ref-type="table-fn"}0.0015cefepime0.69 ± 0.028210 ± 210.0033cefalotin86 ± 1.55.8 ± 0.4415meropenemNH[^b^](#tblfn5){ref-type="table-fn"}0.26 ± 0.0096[^c^](#tblfn6){ref-type="table-fn"}ND[^3][^4][^5][^6][^7]

The induction of chromosomal AmpC β-lactamase in Gram-negative bacteria is known to be one of the resistance mechanisms to β-lactam antibiotics that are hydrolysed by overproduced AmpC.[@dky317-B2]^,^[@dky317-B3] The β-lactam antibiotics differ in their AmpC-inducing abilities, and imipenem and cefoxitin are known to be strong inducers of AmpC.[@dky317-B1]^,^[@dky317-B17] The effect of possessing AmpC-inducing ability on clinical outcomes is unclear, but this inducing ability could lead to a limited choice of antibiotics because overproduced AmpC would cause resistance to a wide variety of β-lactam antibiotics, including third/fourth-generation cephalosporins as well as carbapenems. To evaluate the risk of AmpC induction by cefiderocol itself, a double disc diffusion assay was conducted (Table [S2](#sup1){ref-type="supplementary-material"} and Figures [S1](#sup1){ref-type="supplementary-material"}--[S4](#sup1){ref-type="supplementary-material"}). The assay revealed that cefiderocol did not cause a D-shaped inhibition zone of ceftazidime (indicator disc), though such an inhibition zone was observed with imipenem in *P. aeruginosa* PAO1, *P. aeruginosa* ATCC 27853 and *E. cloacae* ATCC 13047 (Table [S2](#sup1){ref-type="supplementary-material"} and Figures [S1](#sup1){ref-type="supplementary-material"}--[S4](#sup1){ref-type="supplementary-material"}). This D-shaped inhibition zone was not observed when APB was added in the medium nor in the AmpC deletion mutant strain of *P. aeruginosa* PAO1 (AC2064). These results indicated that the formation of a D-shaped inhibition zone with imipenem was owing to the induction of AmpC by imipenem itself. The nitrocefin degradation activity of cell-free extract after exposure to cefiderocol was also compared with that after exposure to imipenem (Figures [S5](#sup1){ref-type="supplementary-material"} and [S6](#sup1){ref-type="supplementary-material"}). It was confirmed that the level of β-lactamases induced by cefiderocol was quantitatively lower than that induced by imipenem in all the experiments with *P. aeruginosa* PAO1, *P. aeruginosa* ATCC 27853 or *E. cloacae* ATCC 13047, and the induction of β-lactamases in *P. aeruginosa* AC2064 was low even in the presence of cefiderocol and imipenem. These results were consistent with the disc diffusion assay and indicated that cefiderocol has a low propensity to induce the AmpC β-lactamases of *P. aeruginosa* and *E. cloacae*.

In summary, this study showed the stability of cefiderocol against chromosomal AmpC β-lactamases of *P. aeruginosa* and *E. cloacae* and the low propensity for induction of AmpC β-lactamase by cefiderocol. These results suggest that cefiderocol could be an effective treatment option for Gram-negative bacterial infections where resistance is mediated by the induction of AmpC β-lactamase.
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[^1]: Tn, transposon insertion.

[^2]: MICs were determined by the broth microdilution method using ID-CAMHB for cefiderocol and CAMHB for the other antibiotics.

[^3]: NH, no hydrolysis detected; ND, not determined (because no hydrolysis was detected).

[^4]: Each *k*~cat~ and *K*~m~ or *K*~i~ value is the mean ± SD of three different measurements.

[^5]: Hydrolysis was too weak to determine the *k*~cat~ value.

[^6]: *K*~i~ values were obtained using 100 μM cefalotin.

[^7]: This value was the detection limit of the spectrophotometer and no hydrolysis was observed at this concentration.
